CA2954082A1 - Methods and compositions for treatment of conditions associated with elevated triglycerides - Google Patents

Methods and compositions for treatment of conditions associated with elevated triglycerides Download PDF

Info

Publication number
CA2954082A1
CA2954082A1 CA2954082A CA2954082A CA2954082A1 CA 2954082 A1 CA2954082 A1 CA 2954082A1 CA 2954082 A CA2954082 A CA 2954082A CA 2954082 A CA2954082 A CA 2954082A CA 2954082 A1 CA2954082 A1 CA 2954082A1
Authority
CA
Canada
Prior art keywords
polypeptide
subject
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2954082A
Other languages
English (en)
French (fr)
Inventor
Zhonghao LIU
Xunshan DING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NGM Biopharmaceuticals Inc
Original Assignee
NGM Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NGM Biopharmaceuticals Inc filed Critical NGM Biopharmaceuticals Inc
Publication of CA2954082A1 publication Critical patent/CA2954082A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
CA2954082A 2014-10-03 2015-10-02 Methods and compositions for treatment of conditions associated with elevated triglycerides Pending CA2954082A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462059682P 2014-10-03 2014-10-03
US62/059,682 2014-10-03
PCT/US2015/053700 WO2016054494A1 (en) 2014-10-03 2015-10-02 Methods and compositions for treatment of conditions associated with elevated triglycerides

Publications (1)

Publication Number Publication Date
CA2954082A1 true CA2954082A1 (en) 2016-04-07

Family

ID=55631597

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2954082A Pending CA2954082A1 (en) 2014-10-03 2015-10-02 Methods and compositions for treatment of conditions associated with elevated triglycerides

Country Status (7)

Country Link
US (3) US10071139B2 (https=)
EP (2) EP3822287A1 (https=)
JP (1) JP6680758B2 (https=)
AU (1) AU2015327900B2 (https=)
CA (1) CA2954082A1 (https=)
ES (1) ES2819866T3 (https=)
WO (1) WO2016054494A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3822287A1 (en) 2014-10-03 2021-05-19 NGM Biopharmaceuticals, Inc. Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
MX2018009513A (es) * 2016-02-04 2019-01-31 Regeneron Pharma Animales no humanos que tienen un gen angptl8 modificado genéticamente.
JP7541810B2 (ja) 2016-03-03 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
WO2017168348A1 (en) * 2016-03-31 2017-10-05 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
KR20180132843A (ko) * 2016-04-08 2018-12-12 리제너론 파아마슈티컬스, 인크. Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법
WO2018094112A1 (en) 2016-11-17 2018-05-24 Regeneron Pharmaceuticals, Inc. Methods of treating obesity with anti-angptl8 antibodies
CA3080148A1 (en) 2017-11-10 2019-05-16 Ngm Biopharmaceuticals, Inc. Angptl8-binding agents and methods of use thereof
US11977081B2 (en) 2017-12-18 2024-05-07 Regeneron Pharmaceuticals, Inc. ANGPTL8 assay and uses thereof
TWI747098B (zh) * 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
CN110694068A (zh) * 2019-11-06 2020-01-17 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (en) * 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
US20140303078A1 (en) * 2011-06-10 2014-10-09 President And Fellows Of Harvard College Modulation of pancreatic beta cell proliferation
CN105073781A (zh) 2013-01-11 2015-11-18 加州生物医学研究所 牛融合抗体
CN105813654B (zh) 2013-10-11 2019-05-31 美国政府(由卫生和人类服务部的部长所代表) Tem8抗体及其用途
EP3822287A1 (en) 2014-10-03 2021-05-19 NGM Biopharmaceuticals, Inc. Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
WO2018094112A1 (en) 2016-11-17 2018-05-24 Regeneron Pharmaceuticals, Inc. Methods of treating obesity with anti-angptl8 antibodies
CA3080148A1 (en) 2017-11-10 2019-05-16 Ngm Biopharmaceuticals, Inc. Angptl8-binding agents and methods of use thereof

Also Published As

Publication number Publication date
JP6680758B2 (ja) 2020-04-15
US20210015902A1 (en) 2021-01-21
EP3201225A4 (en) 2018-05-23
AU2015327900B2 (en) 2020-04-30
AU2015327900A1 (en) 2017-02-02
US20190060408A1 (en) 2019-02-28
US20170143799A1 (en) 2017-05-25
US10071139B2 (en) 2018-09-11
WO2016054494A1 (en) 2016-04-07
EP3201225A1 (en) 2017-08-09
ES2819866T3 (es) 2021-04-19
US10702587B2 (en) 2020-07-07
EP3822287A1 (en) 2021-05-19
EP3201225B1 (en) 2020-08-19
JP2017531613A (ja) 2017-10-26

Similar Documents

Publication Publication Date Title
US10702587B2 (en) Angiopoietin-like protein 8 polypeptide fragments and compositions thereof
US20200325200A1 (en) Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3212226B1 (en) Compositions and methods of use for treating metabolic disorders
JP6704358B2 (ja) 代謝障害を治療するための組成物および使用方法
EP3802621B1 (en) Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities
JP2019056013A (ja) ヒト成長ホルモン類似体を用いた小児成長ホルモン分泌不全症の治療
JPH093098A (ja) 組換え肥満（ｏｂ）蛋白
CN106573072A (zh) 降低血清胆固醇的方法
JP2020147583A (ja) リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
JPWO2019228510A5 (https=)
US20150166629A1 (en) SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT
JP2008526875A (ja) 新規使用
HK40101360A (zh) 用於癌症、肥胖症、代谢紊乱和相关并发症及合并症的精氨酸耗竭剂的组合物和应用
BR112017005986B1 (pt) Complexo que compreende um primeiro heterodímero e um segundo heterodímero, composição farmacêutica e uso do complexo
HK1242595B (en) Compositions and methods of use for treating metabolic disorders
HK1242595A1 (en) Compositions and methods of use for treating metabolic disorders
HK1237790B (en) Compositions and methods of use for treating metabolic disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201001